Apr 09, 2024
Aligos Therapeutics to Participate in the Piper Sandler Spring Biopharma Symposium 2024
Apr 03, 2024
Aligos Therapeutics Announces First Subjects Dosed in the Phase 2a HERALD Study of ALG-055009 in MASH Subjects
Mar 27, 2024
Aligos Therapeutics Presents Positive Clinical Data at APASL 2024 from ALG-055009 and ALG-000184 Phase 1 Studies
Mar 18, 2024
Aligos Therapeutics Announces the Initiation of the Phase 2a HERALD Study of ALG-055009 in MASH Subjects
Mar 12, 2024
Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2023 Financial Results
Mar 05, 2024
Aligos Therapeutics to Announce 4th Quarter 2023 Financial Results on March 12, 2024
Feb 26, 2024
Aligos Therapeutics To Participate in the Leerink Partners Global Biopharma Conference 2024
Feb 20, 2024
Aligos Therapeutics to Host KOL Event to Discuss Phase 2a HERALD Study of ALG-055009 in MASH on March 7, 2024
Feb 13, 2024
Aligos Therapeutics Strengthens Finance Leadership Team with Two New Appointments